The efficient targeted delivery of nucleic acids in vivo provides some of the greatest challenges to the development of genetic therapies. We aim to develop nanocomplex formulations that achieve targeted transfection of neuroblastoma tumours that can be monitored simultaneously by MRI. Here, we have compared nanocomplexes comprising self-assembling mixtures of liposomes, plasmid DNA and one of three different peptide ligands derived from ApoE, neurotensin and tetanus toxin for targeted transfection in vitro and in vivo. Neurotensin-targeted nanocomplexes produced the highest levels of transfection and showed a 4.7-fold increase in transfected luciferase expression over non-targeted nanocomplexes in Neuro-2A cells. Transfection of subcutaneous Neuro-2A tumours in vivo with neurotensin-targeted nanocomplexes produced a 9.3-fold increase in gene expression over non-targeted controls. Confocal microscopy analysis elucidated the time course of DNA delivery with fluorescently labelled nanocomplex formulations in cells. It was confirmed that addition of a gadolinium lipid conjugate contrast agent allowed real time in vivo monitoring of nanocomplex localisation in tumours by MRI, which was maintained for at least 24 h. The peptide-targeted nanocomplexes developed here allow for the specific enhancement of targeted gene therapy both in vitro and in vivo, whilst allowing real time monitoring of delivery with MRI.
Introduction
Gene therapy has great potential for the treatment of a wide range of diseases, with one of the most studied areas being in tumour therapy. However, the introduction of genes into tumour cells in vivo is fraught with problems for naked plasmid DNA, such as enzymatic degradation in the circulation and non-specific, limited efficiency of cellular uptake [1] . Liposome-based nanocomplexes have been used increasingly as delivery vectors for nucleic acid delivery both in vitro and in vivo [2, 3] . This rise in the use of nanocomplexes as delivery vectors is due to the protection they afford the cargo when delivered in vivo, their wide ranging packaging capacities from large DNA constructs to oligonucleotides, their low level of immunogenicity allowing repeated effective delivery and ease of preparation [4, 5] . The versatility of the nanocomplex platform also allows the inclusion of contrast agents for detection by magnetic resonance imaging (MRI) and fluorescence microscopy to monitor biodistribution [6e9], as well as incorporation of targeting peptides to increase the specific uptake in cells of interest [10e12] .
We have previously described the efficient transfection of cultured cells with a self-assembling liposome:peptide:DNA (LPD) nanocomplex formulation comprising cationic DOTMA/DOPE liposomes (L), integrin-targeting peptides (P) and plasmid DNA (D) [13, 14] . Similar formulations were subsequently developed for systemic delivery of plasmid DNA to neuroblastoma tumours with novel nanocomplex formulations that demonstrated the efficacy of PEGylation and of biologically-cleavable linkers within nanocomplex formulations containing integrin-targeting peptides and PEGylated lipids [15e18] . The aim of this new study was to further develop LPD nanocomplex formulations by, i) comparing three new candidate peptide ligands in nanocomplexes to enhance the receptor-targeted transfection of neuroblastoma cells in vitro and in vivo, ii) by modifications of the liposome component of the LPD nanocomplex with fluorescent reagents for microscopic imaging of vector distribution at the cellular level, and iii) by modifying the liposome component with contrast agents for real time imaging of vector distribution by MRI.
The new peptide components comprised targeting ligands for the receptors ApoE [19] , neurotensin [20, 21] and tetanus toxin [22, 23] , which have been reported to be expressed on neuroblastoma cells. Each of the peptides contained, in addition to the targeting sequence, a cationic oligolysine sequence (K 16 ) to bind and condense the plasmid DNA [13] . The targeting specificity of ApoE, Nt and Tet peptides were compared in transfections in murine neuroblastoma cells and further compared and contrasted in a different cell type, human bronchial epithelial cells. Transfections with homologous nanocomplexes containing scrambled versions of the targeting sequences, which should not bind to the relevant receptors and as an additional control, the peptide K 16 , which can condense DNA, but lacks any targeting sequence, were also prepared.
Imaging formulations were prepared by incorporating a fluorophore, rhodamine into the bilayer of the liposome component for fluorescence microscopy and a high relaxivity gadolinium chelate [24] as a MRI contrast agent. The biophysical characteristics, transfection efficiencies, targeting properties and cellular uptake of the nanocomplexes were assessed in vitro. Followed by in vivo administration by direct injection to a subcutaneous, murine neuroblastoma tumour model where gene expression and real time MRI analysis were assessed at three time points up to 24 h with targeted and non-targeted LPD nanocomplex formulations.
Materials and methods

Materials
The lipids (Table 1) 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (DOPE-Rhodamine) and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic acid (gadolinium salt) (bis(14:0 PE)-DTPA (Gd), referred to as G A herein), were purchased from Avanti Polar Lipids Inc., (Alabaster, USA). Diethylenetriaminepentaacetic acid a,ubis(8-stearoylamido-3,6-dioxaoctylamide) gadolinium salt (referred to herein as G S ) was purchased from SigmaeAldrich (Poole, UK). GdDOTA(GAC 12 ) 2 was synthesised as described by Kielar et al. [24] . The plasmid pCI-Luc consists of the luciferase gene from pGL3 (Invitrogen, Paisley, UK) subcloned into pCI (Promega, Southampton, UK). The targeting peptides ApoE (ApoE), Neurotensin (Nt) and Tetanus (Tet), their scrambled, non-targeting equivalents (ApoES, NtS and TetS) and the control peptide K 16 (K 16 ) ( Table 2) were synthesized on a MultiSynTech Syro peptide synthesizer using Fmoc amino acids (Novabiochem, Germany) using methods previously described [15] . The K 16 sequences were synthesised at the N-terminus of each peptide, with the exception of the Nt and NtS peptides, in which the N-terminus is blocked by the pyroglutamic acid (Pyr) residue. Details of the purification and mass spectrometry analysis of these peptides are given in the Supplementary Data.
Liposome formulation
Liposomes were formed with lipid mixtures at specific molar ratios (Table 3) to produce the following; DOTAP:DOPE (DD), DOTAP:DOPE:GdDOTA(GAC 12 ) 2 (DDG), DOTAP:DOPE:DOPE-Rhodamine (DDR) and DOTAP:DOPE:GdDOTA(GAC 12 ) 2 :DOPERhodamine (DDGR). Liposomes were prepared by dissolving the individual lipids in chloroform at 10 mg mL À1 and mixing them together, followed by rotary evaporation to produce a thin lipid film. Lipids were then rehydrated with sterile water whilst rotating overnight and then sonicated for an hour in a water bath to reduce the size to unilamellar liposomes [25] . The liposomes (DDG S R) formulated from DOTAP:DOPE:diethylenetriaminepentaacetic acid a,u-bis(8-stearoylamido-3,6-dioxaoctylamide) gadolinium salt (G s ), and (DDG A R), formulated from DOTAP:DO-PE:bis(14:0 PE)-DTPA (Gd) (G A ), were prepared at the same molar ratio to the liposome DDGR.
Liposome MRI relaxivity
DDGR, DDG S R and DDG A R liposomes were serially diluted in sterile water to give a range of concentrations of 1e0.06 mg mL À1 of the liposomes. MR imaging was performed on a 9.4T VNMRS horizontal bore (Agilent, Palo Alto, USA) using a 59/33 quadrature volume coil (Rapid, Würzburg, Germany), with 200 mL of each of the dilution series in PCR tubes placed into a Perspex holder within the RF coil. The longitudinal relaxivity, r 1 , was determined from a linear fit of 1/T 1 as a function of gadolinium (III) concentration as described previously [7] .
Nanocomplex formation and characterisation
LPD nanocomplex formulations were prepared by mixing aqueous solutions of liposome (L, 1 mg mL À1 ), peptide (P, 10 mg mL À1 ) and plasmid DNA (D, 5 mg mL
À1
) at a weight ratio of 1:4:1 (L:P:D), diluted to 0.01 mg mL À1 (DNA) in OptiMEM (Invitrogen, Paisley, UK) for in vitro transfections, diluted to 0.005 mg mL À1 (DNA) in sterile water for biophysical characterisation and diluted to 0.5 mg mL À1 (DNA) in sterile water for in vivo experiments. The hydrodynamic size and zeta potential of the nanocomplexes were measured by dynamic light scattering (DLS) using a Malvern Nano ZS (Malvern Instruments, Malvern, UK) at a temperature of 25 C, viscosity of 0.89 cP and a refractive index of 1.33.
Cell transfections and viability
The murine neuroblastoma cell line Neuro-2A (ATCC, Manassas, VA, USA) was maintained in Dulbecco's Modified Eagle Medium, 1% non-essential amino acids, 1 mM sodium pyruvate and 10% FCS (Invitrogen, Paisley, UK) at 37 C in a humidified atmosphere in 5% CO 2 . The human bronchial epithelial cell line 16HBE14o-was obtained from Dieter Gruenert [26] , SigmaeAldrich, Poole, UK). The wells were washed and sealed in mounting media (Invitrogen, Paisley, UK) before visualising on a Carl Zeiss LSM710 laser scanning microscope system (Jena, Germany).
Animal model
Female A/J mice (Harlan Laboratories, Oxford, UK), 8e10 weeks old, were injected subcutaneously (s.c.) in the right posterior flank with 1.5 Â 10 6 Neuro-2A cells. After 10 AE 2 days, when tumours had reached 8e12 mm in size, 100 mL of LPD nanocomplexes in 5% glucose containing 50 mg of pCI-Luc plasmid were injected intratumourally. Twenty-four hours after injection, mice were culled, and tumours, livers and kidneys were resected, frozen on liquid nitrogen and stored at À80 C. All in vivo animal experiments were performed with licences issued in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 (UK).
In vivo MR imaging
MRI measurements were performed on a 9.4T VNMRS horizontal bore (Agilent, Palo Alto, USA) using a 59/33 quadrature volume coil (Rapid, Würzburg, Germany). Mice were scanned pre-administration, 4-h and 24 h post administration using a T 1 weighted fast spin echo sequence with the following parameters: TR ¼ 700 ms; ESP ¼ 5.02 ms; ETL ¼ 4; Effective TE ¼ 5.02 ms; NSA ¼ 10; matrix ¼ 256 Â 256; FOV ¼ 40 Â 40 mm; slc ¼ 1 mm, scan time 7 min 28 s. MR images were analysed using ImageJ software (National Institutes of Health, US), with a manually drawn region of interest (ROI) around the tumour. The signal intensity was measured and divided by the signal intensity of muscle to act as an internal reference and the percentage change in signal intensities compared. In addition the volume of each ROI was calculated and summed to give the tumour volume.
Luciferase assay on tumour and tissue extracts
Tumours, livers and kidneys were defrosted on ice, submerged in reporter gene assay lysis buffer (Roche, Basel, Switzerland), homogenized with an IKA homogenizer (IKA, Staufen, Germany), and centrifuged at 13,000 rpm (10,000 Â g) for 10 min at 4 C. The supernatant was removed and centrifuged at 13,000 rpm (10,000Â g) for a further 10 min at 4 C. Luciferase activity in the tissue lysates was measured using the Luciferase Assay System (Promega, Southampton, UK).
Statistical analysis
Data presented in this study are expressed as the mean AE standard deviation and were analysed using a two-tailed, unpaired Student t-test where applicable.
Results
Liposome MRI relaxivity
The relaxivity, r 1 , of the three liposomes formulated with DOTAP, DOPE, DOPE-Rhodamine and with three different lipidic gadolinium complexes, GdDOTA(GAC 12 ) 2 (DDGR), diethylenetriaminepentaacetic acid a,u-bis(8-stearoylamido-3,6-dioxaoctylamide) gadolinium salt (DDG S R) and bis(14:0 PE)-DTPA (Gd) (DDG A R), was Table 2 Amino acid sequence and net charge of the targeted and non-targeted peptides used to formulate the LPD nanocomplexes. (Pyr ¼ pyroglutamic acid).
Peptide
Amino acid sequence Net charge 
measured using MRI to predict the ability of the LPD nanocomplexes to act as a contrast agent for detection and monitoring in vivo. (Fig. 1) . Thus DDGR appeared to be the most sensitive gadoliniumlabelled liposome formulation and was used in subsequent experiments.
Biophysical characterisation of liposomes and LPD nanocomplexes
The biophysical properties of the LPD nanocomplexes were determined to provide insights into the suitability of the nanocomplexes for in vivo use. The parent DOTAP:DOPE (DD) liposomes were 167.6 AE 3.8 nm in diameter (Table 3 ). This liposome was coformulated with peptides Nt, NtS and K 16 and plasmid DNA to produce LPD nanocomplexes in an optimised weight ratio of 1:4:1. These nanocomplexes, ranged in size from 73.2 AE 0.9 nm for DD nanocomplexes with peptide NtS to 91.3 AE 0.6 nm with peptide Nt ( 16 . All of the nanocomplexes formed highly cationic particles ranging from þ20.2 AE 1.8 mV for DDRK 16 nanocomplexes to þ68.9 AE 3.1 mV for DDGK 16 nanocomplexes (Table 4) .
Overall, the DD nanocomplexes were smallest and the DDGRcontaining nanocomplexes were largest regardless of the peptide co-formulated. However, there was no obvious trend in zeta potential measurements of the nanocomplexes related to the different liposome components (Table 4) .
LPD nanocomplexes were also compared for the possible effects of the peptide (ApoE, neurotensin and tetanus targeting sequences, their non-targeting scrambled equivalents and the K 16 peptide lacking a targeting sequence) on particle size and zeta potential of nanocomplexes formed with the DDGR liposome. The sizes of the nanocomplexes ranged from 105.1 AE 3.6 nm for DDGR/NtS formulations to 136.8 AE 7.5 nm for DDGR/K 16 mixtures with no obvious trend associated with specific peptides (Table 5) .
The zeta potentials ranged from þ15.7 AE 7.2 mV for DDGR/TetS formulations to þ49.0 AE 2.4 mV for DDGR/ApoES. ApoE and ApoES peptide nanocomplexes had the highest charges (þ49.0 AE 2.4 and þ42.7 AE 5.6 mV), while the tetanus peptide nanocomplexes had the lowest charge (þ15.7 AE 7.2 and þ27.2 AE 3.6 mV).
All of the nanocomplexes formed had a polydispersity index of less than 0.3, indicating an acceptably homogenous population of particles [27, 28] .
Cell transfections and viability
Assessment of cell transfection efficiency with the LPD nanocomplexes formulated with the liposome DDGR and containing different targeting peptides was performed on two cell lines, Neuro-2A and 16HBE14o-, using a luciferase gene reporter assay. The transfection efficiency of LPD nanocomplexes formed with the Nt peptide was significantly higher in the Neuro-2A cell line than with ApoE or Tet targeting peptides (p < 0.01). LPD nanocomplexes with Nt peptides were 1.6 fold higher than NtS, the scrambled equivalent, and 4.7-fold higher than K 16 nanocomplexes suggesting Nt receptor-enhanced transfection. Similar transfections of the 16HBE14o-cell line showed a smaller, but significant (p < 0.05) enhancement by the Nt peptide when compared to the nontargeted nanocomplexes, but not to the level seen in Neuro-2A cells (Fig. 2) . Fig. 1 . Relaxivity, r 1 , measurements of DDGR, DDG S R and DDG A R liposome formulations at 9.4T. The transfection activity of nanocomplexes formed with the ApoE targeting peptide showed a small, but significant level of enhancement compared to ApoES homologues in 16HBE14o-cells (p < 0.05), whereas there was no significant difference in transfection levels of these nanocomplexes in Neuro-2A cells (Fig. 2) . Nanocomplexes formed with the Tet targeting peptide had higher levels of transfection than their non-targeted TetS homologues in both Neuro-2A cell (2-fold, p < 0.01) and in 16HBE14o-cell (5-fold, p < 0.001) lines, suggesting Tet peptide specificity, but interestingly, Tet LPD nanocomplexes gave lower transfection than the untargeted K 16 nanocomplexes in both cell lines (Fig. 2) .
Further cell transfections were performed to assess the effect of the four liposomes, DD, DDG, DDR and DDGR, on the transfection efficiency of LPD nanocomplex formulations with peptides Nt, NtS, and K 16 and DNA. Nanocomplexes formulated with the unlabelled liposome DD had the highest transfection efficiency with the Nt, NtS and K 16 peptides in Neuro-2A cells when compared to nanocomplexes containing DDG, DDR and DDGR liposomes.
The replacement of the DD liposome with DDR liposomes into the nanocomplexes with the Nt, NtS and K 16 peptides (Fig. 3A) , decreased transfection efficiency uniformly by approximately 18% for all peptide nanocomplexes. The inclusion of the gadolinium lipid into the DDG bilayer reduced transfection efficiencies by 48.3% for the Nt peptide, 65.5% for NtS and 85.6% for the K 16 nanocomplexes. The transfection efficiency of nanocomplexes containing both the rhodamine and gadolinium lipids (DDGR) were reduced to 53.4%, 66.5% and 86.4% of the DD nanocomplexes for Nt, NtS and K 16 nanocomplexes, respectively. However, the transfection efficiency of the targeted Nt nanocomplexes with all four liposomes remained significantly higher than each of the NtS and K 16 nanocomplexes indicating that the substitution of liposomes did not compromise receptor-enhanced transfection (Fig. 3A) . Neuro-2A cell viability, as measured by the MTS cytotoxicity assay, was greater than 80% with all of the nanocomplex formulations tested (Fig. 3B) .
Confocal microscopy
The early stages of uptake kinetics of the nanocomplexes in Neuro-2A cells were investigated by confocal microscopy with images taken at 5 min, 30 min and 2 h after transfection. The cells were analysed for localisation of the rhodamine-labelled lipid and the Cy-5 labelled DNA. Cells were also stained with AlexaFluor488 on F-actin in the cytoplasm and DAPI for visualisation of the nucleus. Fluorescent nanocomplexes were localised to cell membranes after 5 min incubation with none internalised. Internalisation of the nanocomplexes was visualised as early as 30 min with rhodamine and Cy-5 detected inside the cytoplasm of the cells. The intensity of rhodamine and Cy-5 inside the cell increased over time indicating progressive uptake and that internalisation of nanocomplexes was greatest after 2 h of incubation with the majority of the nanocomplexes found in perinuclear regions as suggested by the close proximity of the rhodamine and Cy-5 signals to the DAPI signal of the cell nucleus (Fig. 4) . 
In vivo MR imaging
Assessment of the ability of a gadolinium-labelled nanocomplex to act as an MR contrast agent in vivo was performed in a mouse tumour model. Signal intensities within the tumours were measured pre-, 4 and 24 h after injection to detect nanocomplexes containing the gadolinium-containing lipid within the liposome bilayer. Nt-targeted DDGR nanocomplexes produced a signal intensity enhancement of 21.6 AE 3.1% at 4 h and 9.1 AE 2.4% 24 h in the tumour. Administration of the K 16 non-targeted DDGR nanocomplexes led to a signal enhancement of 16.6 AE 1.2% and 8.2 AE 1.6% at 4 and 24 h after injection respectively. These MRI signal intensities were significantly higher at both 4 h (p < 0.01) and 24 h (p < 0.05) than tumours injected with the saline control ( Fig. 5A  and B ), but no differences were found between the targeted and non-targeted formulations. Tumour volumes, calculated from the images, increased by 43.7% between the 4 h scan and the 24 h scan.
Luciferase assay of tumour and tissue extracts
Luciferase gene reporter assays were performed on tumour and tissue extracts to determine the targeted transfection efficiency in vivo. The administration of the Nt-targeted nanocomplexes into the tumour led to a significant 9.3-fold increase (p < 0.05) in expression of the transfected luciferase reporter gene 24 h after injection compared to the K 16 nanocomplexes, suggesting targeted transfection and a 160-fold increase compared to the saline control group (Fig. 5C ). There were only background levels of luciferase activity in the liver and kidneys of mice injected with Nt and K 16 containing nanocomplexes and those injected with the saline control, with no significant differences found between samples ( Fig. 5D and E) .
Discussion
The targeted delivery of nucleic acids has great therapeutic potential for a wide range of diseases including cancers [29e33]. However, there is still need for the development of targeted synthetic nanoparticle vector formulations. Recently, the addition of contrast agents, for MRI and fluorescence microscopy, into nanocomplex formulations has shown real potential to enable monitoring of therapeutic delivery and localisation in vivo [7,34e36] .
Previously we have demonstrated integrin-mediated targeted nanocomplex delivery of plasmid DNA to tumours in vivo by systemic administration [16, 17] . In addition, several recent studies have also shown the potential of utilising targeting peptides (NCAM and RGD) for tumour delivery of nanocomplexes [37, 38] . Here, we have investigated nanocomplexes with alternative targeting peptides to enhance tumour specificity and incorporation of MRI contrast agents and fluorophores for multimodal imaging of the nanocomplexes in transfected cells and tumours.
MRI relaxivity measurements showed that GdDOTA(GAC 12 ) 2 lipid had the highest r 1 value when compared to DDG S R and DDG A R liposomes (Fig. 1) . This supports previous findings that GdDOTA (GAC 12 ) 2 is superior to the other complexes due to a more favourable water exchange rate and slower local rotation [24, 39] and compares favourably to standard clinically available contrast agents, Gd-DOTA and Gd-DTPA, which have relaxivities on the order of 4 mM À1 s À1 [40, 41] . In addition, the macrocyclic gadolinium chelator, DOTA, used here is far more kinetically stable than acyclic gadolinium chelators, such as DTPA, often used in liposome formulations, as free Gd 3þ ions decomplex from the acyclic chelators more rapidly in vitro and in vivo [42e44]. The high relaxivity and stability of liposomes containing GdDOTA(GAC 12 ) 2 suggests they should have greater potential for in vivo administration than the other two liposomes. All nanocomplexes, as expected, were monodisperse, highly cationic and with a size of around 100 nm amenable to internalization by endocytic processes [45] . The nanocomplexes were all smaller than their parent liposomes (Table 3) , due to the condensing ability of the peptides (Tables 4 and 5 ). The DDGR nanocomplexes were largest when compared to DD, DDG and DDR, but still formed nanocomplexes of an acceptable size (Table 5) . Variations in nanocomplex sizes were most likely due to differences in lipid packaging due to the larger head groups of the rhodamine and Gd-DOTA lipids in the lipid bilayer.
In vitro cell transfection studies in two different cell lines (16HBE14o-and Neuro-2A) were performed to identify the optimal targeting nanocomplexes for gene delivery using the ApoE, neurotensin (Nt) and tetanus (Tet) targeting peptides (Fig. 2) . Nanocomplexes containing the Nt peptide had the highest transfection efficiency in Neuro-2A cells and expression was significantly higher than the NtS scrambled equivalent and more than four-fold higher than K 16 nanocomplexes, suggesting that transfection was enhanced by targeting of nanocomplexes to the neurotensin receptor. The neurotensin-targeted transfection specificity for the Neuro-2A cell line is in agreement with previous studies that have shown neurotensin targets neuroblastoma tumours [46] and neurotensin nanocomplexes targeted to nigral dopamine neurons [47] . The transfection efficiency of nanocomplexes in 16HBE14o-cells with the Nt peptide was also significantly higher than with Nts scrambled control peptide and approximately 2.5-fold higher than the K 16 control nanocomplexes, thus suggesting Nt-receptorenhanced transfection of 16HBE14o-cells, although not to the same level as in the Neuro-2A cells. Consistent with this observation, it was reported previously that neurotensin receptors are expressed on human bronchial epithelial cells [48] . The Nt peptide, therefore offers significantly enhanced cell transfection efficiency in specific cell lines and this may be dependent on the extent of receptor expression although this requires further investigation.
Previous studies have shown uptake of nanocomplexes in endothelial cell lines using ApoE derived peptides, with the aim of crossing the blood brain barrier [49e51] and of ApoE itself for targeted delivery of siRNA to hepatic cells in vitro and in vivo [52] . Here, nanocomplexes containing the ApoE derived targeting peptide displayed a significant enhancement of transfection compared to those containing the ApoES peptide in 16HBE14o-cells. This is consistent with reports that lung epithelial cells display the low density lipoprotein receptor (LDLR) for ApoE [53] . However, although neuronal cells express receptors for ApoE [54] , there was no significant difference in nanocomplex transfections of Neuro-2A cells between ApoE and ApoES peptide-containing nanocomplexes. This may reflect the fact that the ApoE peptide targeting sequence is itself highly cationic when formed as a nanocomplex, due to the twelve additional positively charged lysine and arginine residues present in the ApoE motif in addition to the sixteen lysines. This allows ApoE to bind to ubiquitous heparan sulphate proteoglycan (HSPG) receptors as well as LDLR [54] . As the ApoES peptide contains the same amino acids, but scrambled, it is also highly cationic when formed as a nanocomplex and therefore may retain the capacity to bind to HSPG despite the sequence alterations. Thus, although the experiments have shown that nanocomplexes with the ApoE targeting peptide achieved significant levels of transfection, we are unable from comparisons with the ApoES peptide to demonstrate receptor-mediated enhancement of transfection. Future studies will be required using alternative receptor-blocking agents such as antibodies or receptor cleavage reagents, as described previously [54] to clarify the receptor targeting properties of ApoE-targeted nanocomplexes in both cell lines.
Nanocomplexes containing the tetanus toxin-derived peptides (Tet) had the lowest transfection efficiency of all three targeting peptides across both cell lines, yet they displayed the highest degree of receptor-mediated specificity of transfection. Tet nanocomplexes displayed a significant enhancement of transfection in Neuro-2A cells and a highly significant five-fold enhancement in 16HBE14o-cells over nanocomplexes containing TetS. Previous data supports the evidence for tetanus-targeted specificity as nanoparticles displaying Tetanus toxin C fragment have also shown targeted transfection of neuroblastoma cells [55] and the tetanus toxin receptor is highly expressed in normal human bronchial epithelial cell lines [56, 57] . The nanocomplexes containing Tet, as well as those containing TetS, both display lower transfection levels than K 16 nanocomplexes. The zeta potential of the Tet and TetS nanocomplexes was lower than that of K 16 DDGR nanocomplexes, which may help to partially explain this difference, although this charge difference was not reflected in size measurements. K 16 nanocomplex formulations lack targeting ligands, but are highly cationic allowing electrostatic, binding to anionic cell surface receptors leading to non-specifictransfections in both cell lines. The Tet peptide may also have higher binding affinity for the specific receptor although this has not yet been analysed. Tet-targeted nanocomplexes may be particularly useful in applications where higher degrees of receptor-mediated specificity are required in delivery.
The addition of the rhodamine-containing and gadoliniumcontaining lipids into the nanocomplexes with the Nt, NtS and K 16 peptides (Fig. 3A) , decreased transfection efficiency for all nanocomplexes relative to formulations containing DOTAP/DOPE. However, despite the reduced transfection efficiency, regardless of the liposomal component, LPD nanocomplexes retained their receptor-mediated enhancement of transfection. Incorporation of rhodamine increased the nanocomplex size due presumably to the large hydrophobic rhodamine moiety. Incorporation of the gadolinium lipid had no effect on size of the DD/Nt formulation, but increased both DD/NtS and DD/K 16 . The gadolinium-containing lipid may have had a greater effect than the rhodamine lipid on size (except for DD/Nt) and transfection efficiency when incorporated into the liposomes, as it was present in greater amounts and was accommodated at the expense of the cationic component, DOTAP (Table 3 ). The nanocomplexes containing both rhodamine and gadolinium lipids were correspondingly the largest formulations for each peptide class (Table 4) as might be expected, but their transfection efficiency and targeting specificity, comparing targeted to non-targeted peptide formulations (Fig. 3A) appeared to remain at acceptable levels. Cell viabilities after transfection with nanocomplexes formulated with all of the tested nanocomplexes were found to be at a suitable level for further in vivo studies (Fig. 3B) .
Confocal microscopy analysis of Neuro-2A cells with DDGR/Nt/ Cy5-labelled DNA nanocomplexes (Fig. 4) , suggested that cell binding and entry occurred within the first hour and disassembly of the nanocomplexes occurred between half an hour and 2 h, in agreement with other studies published [58e61].
Since the DDGR/Nt formulation had displayed neuroblastoma cell targeted transfection in vitro, with transfections performed in the presence of serum, it was selected for in vivo experiments. Proof of principle for both targeted transfection and real time imaging of vector distribution by MRI within a subcutaneous neuroblastoma tumour was performed. To maximise the chances of detecting any difference in targeting versus non-targeting transfection in vivo and MRI contrast effect, the Nt peptide was compared to K 16 peptide and saline, injected directly into the tumour. A significant increase in signal intensity was visualised due to the presence of the nanocomplexes 4 h post administration. The decrease in signal intensity at 24 h compared to 4 h is most likely due to a combination of clearance of the nanocomplexes from the tumour and the increase in tumour size, due to growth, leading to a dilution of the gadolinium within the tumour (Fig. 5A and B) . The MR signal enhancement produced by the administration of the nanocomplexes is of the same order of magnitude as other paramagnetic liposome-based tumour therapy delivery vectors [7, 62] . However, further optimisation of the nanocomplex composition could increase the amount of gadolinium and hence further improve the signal enhancement. In addition, the rhodamine lipid could be utilised ex vivo to validate the MRI results by visualising the presence of the nanocomplexes within the tumour [7, 62, 63] .
The targeted nanocomplexes, DDGR/Nt produced a large increase in luciferase expression when compared to the nontargeted DDGR/K 16 nanocomplexes (Fig. 5C) , despite the similar amount of nanocomplex present in the tumour as suggested by the MRI. This demonstrates that the targeting efficiency of the neurotensin-targeted nanoparticles relative to the untargeted nanocomplexes is retained in vivo, as previously seen in the in vitro experiments. Only background levels of luciferase activity were detected in the liver and kidneys ( Fig. 5D and E), which suggests that there was minimal shedding of nanocomplexes from the tumour into the circulation, an essential feature for any potential clinically translatable methodology.
The targeted specificity of transfection contrasted strongly with the MRI data, which revealed no contrast enhancement with the Nt-targeted relative to the untargeted K 16 formulation. This suggests that the MRI contrast was produced by accumulation of the nanocomplex-associated gadolinium chelate within the tumour, but was not influenced by cell uptake. Whereas transfected luciferase gene expression requires cell uptake, nuclear transport, transcription and translation. Transfection, in contrast to MRI, appears to be a highly receptor-dependent process, due most likely to improved cell binding and internalisation of the nanocomplex, increasing the amount of internalised DNA per cell.
In vivo transfections were performed in this study by direct, intratumoural administration rather than by systemic administration, as we have reported previously [16, 17] . This approach was adopted to maximise delivery of the nanocomplexes to the tumour to assess the concept that gadolinium-labelling of nanocomplexes enables them to be detected in vivo and to evaluate the tumour targeting properties of the Nt peptide within the nanocomplex formulation in vivo. This study has shown that real time imaging by MRI can be used to track the distribution and persistence of a gadolinium-labelled nanocomplex in vivo, but not necessarily the nanocomplexes functionality. This could be assessed in future studies by analysis of tumours by luminescence and fluorescence imaging systems to monitor luciferase and GFP reporter gene expression for comparison with MRI data. The tools developed in this study will now enable such studies to be performed.
Conclusions
This study describes the development LPD nanocomplexes for targeted tumour cell transfection and for monitoring of vector distribution in real time by MRI. In addition fluorescence labelling was incorporated for post transfection cellular analysis of vector distribution. LPD nanocomplexes formulated with three different targeting peptides, ApoE, neurotensin and tetanus, displayed targeted transfection in both bronchial epithelial and neuroblastoma cell lines in vitro. Neurotensin nanocomplexes demonstrated targeted transfection in an in vivo neuroblastoma tumour model. These highly versatile nanocomplexes have real potential as research tools in the future development of nucleic acid therapies for cancers.
